Pharmaceutical combination
US-2016250218-A1 · Sep 1, 2016 · US
Medicaments for the treatment or prevention of fibrotic diseases
US10154990B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10154990-B2 |
| Application number | US-201514982179-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 29, 2015 |
| Priority date | Dec 24, 2004 |
| Publication date | Dec 18, 2018 |
| Grant date | Dec 18, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating systemic scleroderma, which comprises administering to a patient in need thereof a therapeutically effective amount of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a salt thereof. 2. The method as recited in claim 1 wherein 3-Z- [1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone is in the form of the monoethanesulfonate salt. 3. The method as recited in claim 1 further comprising administering an additional pharmacologically active substance selected from the group consisting of anticholinergic agents, beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK 1 antagonists, LTD4 antagonists, EGFR inhibitors and endothelin-antagonists in combination with the 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or salt thereof. 4. The method of claim 3 , wherein the 3-Z-[1-(4-(N-((4 -methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or salt thereof, and the additional pharmacologically active substance together comprise a pharmaceutical composition that further comprises one or more pharmaceutically acceptable carriers or excipients. 5. A method for treating systemic scleroderma comprising administering a therapeutically effective amount of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone in the form of the monoethanesulfonate salt, to a patient in need thereof.
Assignees
Inventors
Classifications
- A61K31/404Primary
Indoles, e.g. pindolol · CPC title
Dispersions; Emulsions · CPC title
Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Non condensed pyridines; Hydrogenated derivatives thereof · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10154990B2 cover?
- The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevent…
- Who is the assignee on this patent?
- Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification A61K31/404. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).